Login to Your Account

Novelmed Takes ‘Complementary’ Approach to MAbs

By Marie Powers
Staff Writer

Monday, October 14, 2013

After a decade of work in the lab, Novelmed Therapeutics Inc. has its sights set on moving its lead compound into human studies in paroxysmal nocturnal hemoglobinuria (PNH) and two models of age-related macular degeneration (AMD). 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription